ARDX
Price
$3.34
Change
-$0.04 (-1.18%)
Updated
Oct 2 closing price
Capitalization
880.42M
26 days until earnings call
Intraday BUY SELL Signals
RNAC
Price
$7.36
Change
+$0.14 (+1.94%)
Updated
Oct 2 closing price
Capitalization
218.14M
33 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARDX vs RNAC

ARDX vs RNAC Comparison Chart in %
View a ticker or compare two or three
VS
ARDX vs. RNAC commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDX is a Hold and RNAC is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ARDX vs RNAC: Fundamental Ratings
ARDX
RNAC
OUTLOOK RATING
1..100
5769
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8564
P/E GROWTH RATING
1..100
3433
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RNAC's Valuation (98) in the Biotechnology industry is in the same range as ARDX (100). This means that RNAC’s stock grew similarly to ARDX’s over the last 12 months.

ARDX's Profit vs Risk Rating (79) in the Biotechnology industry is in the same range as RNAC (100). This means that ARDX’s stock grew similarly to RNAC’s over the last 12 months.

ARDX's SMR Rating (97) in the Biotechnology industry is in the same range as RNAC (100). This means that ARDX’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's Price Growth Rating (64) in the Biotechnology industry is in the same range as ARDX (85). This means that RNAC’s stock grew similarly to ARDX’s over the last 12 months.

RNAC's P/E Growth Rating (33) in the Biotechnology industry is in the same range as ARDX (34). This means that RNAC’s stock grew similarly to ARDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARDXRNAC
RSI
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 1 day ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (ARDX: $3.34 vs. RNAC: $7.36)
Brand notoriety: ARDX and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARDX: 87% vs. RNAC: 158%
Market capitalization -- ARDX: $880.42M vs. RNAC: $218.14M
ARDX [@Biotechnology] is valued at $880.42M. RNAC’s [@Biotechnology] market capitalization is $218.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARDX’s FA Score shows that 0 FA rating(s) are green while RNAC’s FA Score has 1 green FA rating(s).

  • ARDX’s FA Score: 0 green, 5 red.
  • RNAC’s FA Score: 1 green, 4 red.
According to our system of comparison, RNAC is a better buy in the long-term than ARDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARDX’s TA Score shows that 5 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).

  • ARDX’s TA Score: 5 bullish, 3 bearish.
  • RNAC’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARDX is a better buy in the short-term than RNAC.

Price Growth

ARDX (@Biotechnology) experienced а -2.34% price change this week, while RNAC (@Biotechnology) price change was -0.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.

Reported Earning Dates

ARDX is expected to report earnings on Oct 29, 2026.

RNAC is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARDX
Daily Signal:
Gain/Loss:
RNAC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CCL25.760.69
+2.75%
Carnival Corporation Ltd.
CLLS1.430.03
+2.14%
Cellectis SA
FFAI1.23-0.02
-1.60%
Faraday Future Intelligent Electric Inc.
SLDB6.85-0.13
-1.86%
Solid Biosciences
PLSE47.90-1.93
-3.87%
Pulse Biosciences

ARDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
-1.18%
VCYT - ARDX
45%
Loosely correlated
+3.67%
CABA - ARDX
36%
Loosely correlated
+5.82%
RNAC - ARDX
35%
Loosely correlated
+1.94%
IMNM - ARDX
33%
Loosely correlated
+0.05%
ELVN - ARDX
33%
Loosely correlated
+1.64%
More

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
+1.94%
TAOX - RNAC
91%
Closely correlated
+0.46%
PALI - RNAC
81%
Closely correlated
+0.70%
EDIT - RNAC
46%
Loosely correlated
+3.97%
NKTX - RNAC
45%
Loosely correlated
+0.59%
SLDB - RNAC
41%
Loosely correlated
-1.86%
More